Public consultation on our new approach to prioritising guidance now open
The consultation seeks your views about our plans to make topic selection and prioritisation more integrated, effective and timely.
The consultation seeks your views about our plans to make topic selection and prioritisation more integrated, effective and timely.
New one-a-day tablet for people with severe hair loss due to alopecia areata recommended by NICE
Our guidance recommends better targeting of antibiotics to those at the highest risk of suspected sepsis to ensure the right people receive treatment.
Around 300 people are set to benefit following NICE’s recommendation of talazoparib for treating a type of locally advanced or metastatic breast cancer in final draft guidance published today (19 January 2024).
A further 1.4 million people who have an increased risk for progression to severe COVID-19 will be eligible for Paxlovid if they test positive.
More people with chronic obstructive pulmonary disease (COPD) could soon access rehabilitation programmes after draft guidance from NICE conditionally recommended two technologies to provide digital services to NHS patients.
Page 5 of 29